{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CDX-1127", "query": { "intervention": "CDX-1127" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 14, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CDX-1127&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T17:42:12.080Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02335918", "title": "A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "Ovarian Carcinoma-Enrollment Completed", "Colorectal Cancer (CRC)-Enrollment Completed", "Renal Cell Carcinoma (RCC) (Phase ll Only)", "Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed" ], "interventions": [ { "name": "Combination of varlilumab and nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2015-01", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2019-12-09", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 19, "location_summary": "Tucson, Arizona • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02335918" }, { "nct_id": "NCT03688178", "title": "DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Varlilumab", "type": "BIOLOGICAL" }, { "name": "Td", "type": "BIOLOGICAL" }, { "name": "Unpulsed DCs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Annick Desjardins, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2020-08-26", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03688178" }, { "nct_id": "NCT04941287", "title": "Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Distal Bile Duct Adenocarcinoma", "Metastatic Gallbladder Carcinoma", "Metastatic Intrahepatic Cholangiocarcinoma", "Recurrent Distal Bile Duct Adenocarcinoma", "Recurrent Gallbladder Carcinoma", "Recurrent Intrahepatic Cholangiocarcinoma", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Gallbladder Cancer AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Unresectable Liver Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cobimetinib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Varlilumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 57, "start_date": "2021-12-15", "completion_date": "2026-04-29", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04941287" }, { "nct_id": "NCT02302339", "title": "A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "glembatumumab vedotin", "type": "DRUG" }, { "name": "glembatumumab vedotin and varlilumab", "type": "DRUG" }, { "name": "glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)", "type": "DRUG" }, { "name": "glembatumumab vedotin and CDX-301", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2014-11", "completion_date": "2018-10-03", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 14, "location_summary": "Los Angeles, California • San Francisco, California • Fort Myers, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302339" }, { "nct_id": "NCT02413827", "title": "A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Unresectable Stage III or Stage IV Melanoma" ], "interventions": [ { "name": "Combination of varlilumab and ipilimumab", "type": "DRUG" }, { "name": "Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2015-04", "completion_date": "2016-11-09", "has_results": false, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 8, "location_summary": "San Francisco, California • Santa Rosa, California • Aurora, Colorado + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02413827" }, { "nct_id": "NCT04081688", "title": "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab 1200 MG in 20 ML Injection", "type": "DRUG" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Varlilumab 3 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2019-09-11", "completion_date": "2024-04-30", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04081688" }, { "nct_id": "NCT02270372", "title": "Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Ovarian Carcinoma" ], "interventions": [ { "name": "ONT-10, Varlilumab combination", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Cascadian Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2014-11", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2018-05-17", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 4, "location_summary": "Birmingham, Alabama • Aurora, Colorado • New York, New York + 1 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02270372" }, { "nct_id": "NCT01460134", "title": "A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma", "Chronic Lymphocytic Leukemia", "Mantle Cell Lymphoma", "Marginal Zone B Cell Lymphoma)", "Any T-cell Malignancy", "Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma", "Hormone-refractory Prostate Adenocarcinoma, Ovarian Cancer", "Colorectal Adenocarcinoma, Non-small Cell Lung Cancer)", "Burkett's Lymphoma", "Primary Lymphoma of the Central Nervous System" ], "interventions": [ { "name": "CDX-1127", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2011-10", "completion_date": "2017-10-16", "has_results": false, "last_update_posted_date": "2018-01-31", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Stanford, California • Rochester, Minnesota + 7 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Stanford", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01460134" }, { "nct_id": "NCT02924038", "title": "A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Malignant Glioma", "Astrocytoma, Grade II", "Oligodendroglioma", "Glioma, Astrocytic", "Oligoastrocytoma, Mixed" ], "interventions": [ { "name": "IMA950", "type": "BIOLOGICAL" }, { "name": "poly-ICLC", "type": "BIOLOGICAL" }, { "name": "Varlilumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Nicholas Butowski", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-04-03", "completion_date": "2022-12-31", "has_results": true, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924038" }, { "nct_id": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinoma, Renal Cell", "Kidney Diseases", "Kidney Neoplasms", "Urogenital Neoplasms", "Urologic Diseases", "Urologic Neoplasms", "Neoplasms by Histologic Type", "Neoplasms", "Clear-cell Metastatic Renal Cell Carcinoma", "Melanoma", "Triple Negative Breast Cancer", "Bladder Cancer", "Head and Neck Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Combination of Varlilumab and Atezolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-10", "completion_date": "2017-05-22", "has_results": false, "last_update_posted_date": "2018-04-30", "last_synced_at": "2026-09-02T17:42:12.080Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02543645" } ] }